Form 8-K - Current report:
SEC Accession No. 0001213900-24-077779
Filing Date
2024-09-11
Accepted
2024-09-11 17:26:06
Documents
15
Period of Report
2024-09-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0213723-8k_nkgen.htm   iXBRL 8-K 34968
2 SIXTH AMENDMENT TO FORWARD PURCHASE AGREEMENT, DATED AS OF SEPTEMBER 5, 2024, AM ea021372301ex10-1_nkgen.htm EX-10.1 19752
  Complete submission text file 0001213900-24-077779.txt   281602

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nkgn-20240905.xsd EX-101.SCH 3882
4 XBRL DEFINITION FILE nkgn-20240905_def.xml EX-101.DEF 26779
5 XBRL LABEL FILE nkgn-20240905_lab.xml EX-101.LAB 37008
6 XBRL PRESENTATION FILE nkgn-20240905_pre.xml EX-101.PRE 25403
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0213723-8k_nkgen_htm.xml XML 6001
Mailing Address 3001 DAIMLER ST, SANTA ANA CA 92705
Business Address 3001 DAIMLER ST, SANTA ANA CA 92705 (949) 396-6830
NKGen Biotech, Inc. (Filer) CIK: 0001845459 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 241293336
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)